Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Luquet

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Blood Advances|September 6, 2023
Vitamin C and D supplementation in acute myeloid leukemiaPierre Luc Mouchel, Emilie Bérard, Suzanne Tavitian, et al.
Cancers|May 10, 2020
CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating AgentsFrançois Vergez, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
BMC Medical Genomics|February 1, 2012
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samplesDiane Raingeard de la Blétière, Odile Blanchet, Pascale Cornillet-Lefèbvre, et al.
Leukemia Research|January 12, 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry studyIbrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, et al.
Cancer Medicine|February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapyHarmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.
Leukemia & Lymphoma|May 31, 2022
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry studyNoémie Gadaud, Harmony Leroy, Emilie Bérard, et al.
Cancers|July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry StudyPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Blood Advances|September 6, 2023
Vitamin C and D supplementation in acute myeloid leukemiaPierre Luc Mouchel, Emilie Bérard, Suzanne Tavitian, et al.
Cancers|May 10, 2020
CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating AgentsFrançois Vergez, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
BMC Medical Genomics|February 1, 2012
Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samplesDiane Raingeard de la Blétière, Odile Blanchet, Pascale Cornillet-Lefèbvre, et al.
Leukemia Research|January 12, 2024
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry studyIbrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, et al.
Cancer Medicine|February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapyHarmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid LeukemiaAlban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Oncotarget|February 22, 2018
SNP-array lesions in core binding factor acute myeloid leukemiaNicolas Duployez, Elise Boudry-Labis, Christophe Roumier, et al.
Leukemia & Lymphoma|May 31, 2022
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry studyNoémie Gadaud, Harmony Leroy, Emilie Bérard, et al.
Cancers|July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry StudyPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Pageof 7